Publication:
Hepatitis C virus genotyping methods: Evaluation of amplisens® HCV-1/2/3-FRT compared to sequencing method

Simple item page
dc.citedby2
dc.contributor.affiliationsFaculty of Medicine and Health Sciences
dc.contributor.affiliationsUniversiti Sains Islam Malaysia (USIM)
dc.contributor.affiliationsUniversiti Kebangsaan Malaysia (UKM) Medical Centre
dc.contributor.authorMohamed N.A.en_US
dc.contributor.authorRashid Z.Z.en_US
dc.contributor.authorWong K.K.en_US
dc.date.accessioned2024-05-29T02:00:55Z
dc.date.available2024-05-29T02:00:55Z
dc.date.issued2014
dc.description.abstractBackground: Hepatitis C virus (HCV) genotyping is important for treatment and epidemiological purposes. The objective of this study was to evaluate the performance of AmpliSens® HCV-1/2/3-FRT kit in comparison to sequencing method for genotyping. Methods: A total of 17 samples collected from December 2009 to January 2011 were analyzed. Reverse transcriptase polymerase chain reaction (PCR) was performed, followed by sequencing technique. Results were analyzed based on sequence information in GenBank. A second genotyping method (AmpliSens® HCV-1/2/3-FRT) was done, which differentiates HCV genotypes by means of real-time hybridization-fluorescence detection. Results: From 17 samples, four were untypeable by AmpliSens® HCV-1/2/3-FRT. Eleven of 13 (84.6%) results showed concordant genotypes. A specimen that was determined as genotype 3a by sequencing was genotype 1 by the AmpliSens® HCV-1/2/3-FRT. Another specimen that was genotype 1 by sequencing was identified as genotype 3 by AmpliSens® HCV-1/2/3-FRT. Conclusion: HCV genotyping with AmpliSens® HCV-1/2/3-FRT using real-time PCR method provides a much simpler and more feasible workflow with shorter time compared to sequencing method. There was good concordance compared to sequencing method. However, more evaluation studies would be required to show statistical significance, and to troubleshoot discordant results. AmpliSens® HCV-1/2/3-FRT does differentiate between genotype but not until subtype level.en_US
dc.description.natureFinalen_US
dc.identifier.CODENJCANE
dc.identifier.doi10.1002/jcla.21670
dc.identifier.epage228
dc.identifier.issn8878013
dc.identifier.issue3
dc.identifier.pmid24478138
dc.identifier.scopus2-s2.0-84899621138
dc.identifier.spage224
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84899621138&doi=10.1002%2fjcla.21670&partnerID=40&md5=018ce6653e263d7521536a21c8ca2273
dc.identifier.urihttps://oarep.usim.edu.my/handle/123456789/10144
dc.identifier.volume28
dc.languageEnglish
dc.language.isoen_USen_US
dc.publisherWiley-Liss Inc.en_US
dc.relation.ispartofJournal of Clinical Laboratory Analysis
dc.sourceScopus
dc.subjectAmpliSens® HCV-1/2/3-FRTen_US
dc.subjectHCV genotypeen_US
dc.subjectHCV subtypeen_US
dc.subjectReal timeen_US
dc.subjectRT-PCRen_US
dc.subjectSequencing methodsen_US
dc.titleHepatitis C virus genotyping methods: Evaluation of amplisens® HCV-1/2/3-FRT compared to sequencing methoden_US
dc.title.alternativeJ. Clin. Lab. Anal.en_US
dc.typeArticleen_US
dspace.entity.typePublication

Files

Collections

Scopus